The new partnership between Henry Schein (HSIC) and GoTu Technology puts dental staffing and workforce flexibility in focus for investors, alongside the separate removal of Henry Schein from the Russell 1000 Dynamic Index.

Henry Schein’s recent 30 day share price return of 11.84% and 90 day share price return of 17.29% sit alongside a 1 year total shareholder return of 17.93%. This suggests improving momentum as the GoTu partnership and index removal reset the story.

If this staffing focused news has you thinking about where else long term themes might play out, it could be worth scanning 40 healthcare AI stocks

After Henry Schein’s recent double digit gains and the GoTu partnership putting fresh attention on its services, the next issue is price: does it make more sense to commit at today’s level or wait for a pullback?

Most Popular Narrative: 1.6% Undervalued

Henry Schein's most followed narrative pegs fair value at $88.07, only slightly above the recent $86.62 close, which keeps valuation firmly in focus after the GoTu news.

The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings, and expects over 50% of non-GAAP operating income to come from these segments, supporting structurally higher gross margins and likely driving earnings expansion.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that earnings expansion story? The narrative leans on a specific mix of revenue growth, margin uplift and a lower future earnings multiple. The exact blend may surprise you.

Result: Fair Value of $88.07 (UNDERVALUED)

However, Henry Schein’s story could look different if competitive pricing in core supplies intensifies or if dental staffing shortages persist and keep patient volumes under pressure.

Another View: What Henry Schein’s P/E Ratio Is Telling You

While the most followed Henry Schein narrative points to a fair value of $88.07, the current 25x P/E looks expensive against peer averages of 21x, yet roughly in line with the US Healthcare industry at 25.9x and close to an estimated fair ratio of 25.9x. That mix of signals raises a simple question for investors: is there more upside being priced in than the analysts’ modest upside suggests, or is this roughly where the market could settle?

See what the numbers say about this price, find out in our valuation breakdown. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If all this leaves you sensing a mixed mood around Henry Schein, it is worth reviewing the full picture yourself and weighing up the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Henry Schein?

If Henry Schein has sharpened your focus, do not stop here. Broaden your watchlist with other stocks that fit clear, fundamentals based themes using targeted screeners.

• Pinpoint potential value opportunities by scanning 41 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them yet.
• Strengthen your income stream by checking 8 dividend fortresses designed for investors who want higher yields without ignoring resilience.
• Lower the chance of unwanted surprises by reviewing 74 resilient stocks with low risk scores focused on companies with more resilient overall risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.